Universal CO. Ltd. Pharmaceutical Import Profile — Myanmar (DGFT 2022–2026)

Name: Universal CO. Ltd. Pharmaceutical Import Records from India — 6 Products, $1.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Universal CO. Ltd. — Pharmaceutical Importer Profile (2026) | 6 Products, $1.3M Trade | TransData Nexus

Universal CO. Ltd.

Pharmaceutical Importer · Myanmar · Analgesics & Antipyretics Focus · $1.3M Total Trade · DGFT Verified

Universal CO. Ltd. is a pharmaceutical importer based in Myanmar with a total trade value of $1.3M across 6 products in 5 therapeutic categories. Based on 26 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Universal CO. Ltd. sources from 1 verified Indian supplier, with Lincoln Pharmaceuticals Limited accounting for 100.0% of imports.

Universal CO. Ltd. — Import Portfolio & Supplier Network

Universal CO. Ltd. import network — 6 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Universal CO. Ltd.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Lincoln Pharmaceuticals Limited	$2.3M	73	100.0%

Universal CO. Ltd. sources from 1 verified Indian supplier across 33 distinct formulations. The sourcing is highly concentrated — Lincoln Pharmaceuticals Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Universal CO. Ltd. Import?

Formulation	Value	Ships
Chlorzoxazone, diclofenac sodium &	$130.1K	3
Dicyclo mine hcl with paracetamol	$113.0K	3
Hyoscine butylbromide tablets BP	$110.8K	3
Cetirizine hydrochloride tablets	$109.5K	3
Acetaminophen oral solution 125 MG/5 ML	$109.0K	3
Ciprofloxacin tablets BP (proxic-500)	$107.1K	3
Aceclofenac tablets (acel) (5953x10x10t)	$107.0K	3
Amlodipine besylate tablets USP	$106.6K	3
Nystatin for oral suspension USP i	$106.1K	3
Ranitidine tablets USP USP (ranid-150)	$105.4K	3
Povidone iodine and metronidazole	$105.3K	3
Diclofenac diethylamine, linseed oil	$105.3K	3
Lansoprazole delayed release capsules	$104.4K	3
Levocetirizine dihydrochloride mouth	$104.4K	3
Furosemide tablets BP 40 MG (furose)	$103.8K	3

Import Portfolio — Top 6 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Diclofenac	Analgesics & Antipyretics	$400.0K	8	0.1%	10
2	Cetirizine	Antihistamines & Allergy	$300.0K	6	0.2%	15
3	Acetaminophen	Analgesics & Antipyretics	$150.0K	3	0.1%	19
4	Nifedipine	Cardiovascular	$150.0K	3	0.5%	12
5	Nystatin	Antifungals	$150.0K	3	0.3%	8
6	Ranitidine	Gastrointestinal	$150.0K	3	1.2%	3

Universal CO. Ltd. imports 6 pharmaceutical products across 5 categories into Myanmar totaling $1.3M.

Universal CO. Ltd. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Universal Co. Ltd. is a prominent pharmaceutical importer and distributor based in Yangon, Myanmar. Established in 1992, the company has played a significant role in Myanmar's healthcare sector by providing a wide range of pharmaceutical products to meet the nation's medical needs. Operating from its headquarters at 52/B, Pan Hlaing Housing, Pan Hlaing St., Kyeemyindaing Township, Yangon, Universal Co. Ltd. has built a reputation for reliability and quality in the distribution of medical supplies. (myanmaryellowpages.biz)

As a key player in Myanmar's pharmaceutical distribution network, Universal Co. Ltd. sources a diverse array of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's strategic partnerships with international suppliers, particularly from India, have enabled it to offer a comprehensive portfolio of medications across various therapeutic categories. This extensive product range underscores Universal Co. Ltd.'s commitment to enhancing the accessibility and quality of healthcare in Myanmar.

2Distribution Network

Universal Co. Ltd. operates a well-established distribution network within Myanmar, ensuring the efficient delivery of pharmaceutical products nationwide. The company's logistics capabilities are supported by a central warehouse located in Yangon, which serves as the hub for inventory management and distribution. From this central point, products are dispatched to various regions, including Mandalay, Naypyitaw, and other major cities, facilitating timely access to essential medications across the country.

In addition to its domestic operations, Universal Co. Ltd. has explored opportunities to extend its reach beyond Myanmar's borders. While the primary focus remains on the domestic market, the company's strategic positioning and established supply chain relationships position it to potentially serve neighboring countries in the future. This expansion could further solidify its role as a key player in the Southeast Asian pharmaceutical distribution landscape.

3Industry Role

Within Myanmar's pharmaceutical supply chain, Universal Co. Ltd. functions primarily as a wholesaler and distributor. The company imports finished pharmaceutical formulations from international suppliers, particularly from India, and distributes these products to various healthcare providers, including hospitals, clinics, and retail pharmacies. By acting as an intermediary between manufacturers and end-users, Universal Co. Ltd. plays a crucial role in ensuring the availability and accessibility of a wide range of medications throughout Myanmar.

The company's operations are characterized by a focus on quality assurance and regulatory compliance. Universal Co. Ltd. adheres to the National Drug Law of Myanmar, which mandates the registration of pharmaceutical products with the Food and Drug Administration (FDA) before importation and distribution. This commitment to regulatory standards ensures that all imported products meet the safety and efficacy requirements set forth by Myanmar's health authorities. (servicetrade.gov.mm)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Universal CO. Ltd.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Universal Co. Ltd. demonstrates a high degree of sourcing concentration, with a significant portion of its pharmaceutical imports originating from a single supplier: Lincoln Pharmaceuticals Limited. Between 2022 and 2026, the company imported approximately $2.3 million worth of products from Lincoln Pharmaceuticals Limited, accounting for 100% of its pharmaceutical imports from India during this period.

This sourcing strategy indicates a strong and stable relationship between Universal Co. Ltd. and Lincoln Pharmaceuticals Limited. The consistent volume of imports suggests mutual trust and reliability in the supply chain. However, such a concentrated sourcing approach also presents potential risks, including supply chain disruptions due to geopolitical events, regulatory changes, or operational challenges faced by the supplier. To mitigate these risks, Universal Co. Ltd. may consider diversifying its supplier base and establishing contingency plans to ensure a continuous supply of essential pharmaceutical products.

2Supply Chain Resilience

The resilience of Universal Co. Ltd.'s supply chain is closely tied to its exclusive partnership with Lincoln Pharmaceuticals Limited. While this relationship has facilitated a steady supply of pharmaceutical products, it also means that the company is highly dependent on a single supplier for its imports. This dependency could pose challenges in the event of supply chain disruptions, such as production delays, shipping issues, or changes in regulatory policies affecting the supplier.

Importing Pharmaceuticals into Myanmar — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Myanmar

1Regulatory Authority & Framework

In Myanmar, the regulation of pharmaceutical products is overseen by the Food and Drug Administration (FDA), which operates under the Ministry of Health. The FDA is responsible for ensuring the safety, efficacy, and quality of drugs imported, manufactured, and sold within the country. The National Drug Law, enacted in 1992, provides the legal framework for the registration, licensing, and regulation of pharmaceutical products and establishments. (servicetrade.gov.mm)

The FDA's role encompasses the registration of pharmaceutical products, granting of licenses for manufacturing, importing, exporting, storing, distributing, and selling drugs, and enforcing quality assurance standards. Additionally, the FDA stipulates terms and conditions related to labeling and advertising of drugs, ensuring that all pharmaceutical products meet the required standards before they enter the Myanmar market. (servicetrade.gov.mm)

2Import Licensing & GMP

Import licensing in Myanmar is a critical component of the pharmaceutical regulatory framework. Companies wishing to import pharmaceutical products must obtain an Import License from the Ministry of Commerce. The application process involves submitting various documents, including a proforma invoice, sales contract, and import price confirmation endorsed by the Myanmar Pharmaceutical & Medical Equipment Entrepreneurs' Association (MPMEEA).

Universal CO. Ltd. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Universal Co. Ltd.'s product strategy focuses on importing a diverse range of pharmaceutical products across multiple therapeutic categories to meet the varied healthcare needs of the Myanmar population. The company's import portfolio includes analgesics and antipyretics, antihistamines and allergy medications, cardiovascular drugs, and antifungal agents.

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Universal CO. Ltd.

What products does Universal CO. Ltd. import from India?

Universal CO. Ltd. imports 6 pharmaceutical products across 5 categories. Top imports: Diclofenac ($400.0K), Cetirizine ($300.0K), Acetaminophen ($150.0K), Nifedipine ($150.0K), Nystatin ($150.0K).

Who supplies pharmaceuticals to Universal CO. Ltd. from India?

Universal CO. Ltd. sources from 1 verified Indian suppliers. The primary supplier is Lincoln Pharmaceuticals Limited (100.0% of imports, $2.3M).

What is Universal CO. Ltd.'s total pharmaceutical import value?

Universal CO. Ltd.'s total pharmaceutical import value from India is $1.3M, based on 26 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Universal CO. Ltd. focus on?

Universal CO. Ltd. imports across 5 categories. The largest: Analgesics & Antipyretics (42.3%), Antihistamines & Allergy (23.1%), Cardiovascular (11.5%).

Get Full Universal CO. Ltd. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.